

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE List of Information Cited by Applicant Page 1 of 1	ATTY. DOCKET NO. 0269.01/C	SERIAL NO. 10/652,814
	APPLICANT Unger	
	FILING DATE August 29, 2003	GROUP 1633

U.S. PATENT DOCUMENTS							
EXAM. INITIAL		DOCUMENT NUMBER	DATE	NAME	C L S	SUB- CLS	FILE DATE
	AA	6,489,458	12/3/2002	HACKETT, ET AL.			
	AB	US 2003/087323	10/23/2009	UNGER			
	AC	US 2004/0038303	2/26/2004	UNGER			
	AD	US 2004/0038406	2/26/2004	UNGER			
	AE	US 2008/0113932 A1	05/15/2008	SLATON, ET AL.			
	AF	US 2008/0220072 A1	09/11/2008	UNGER, ET AL.			
	AG	US 2009/0238883	9/24/2009	KREN, ET AL.			

FOREIGN PATENT DOCUMENTS							
EXAM. INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLS	SUB CLS	TRANS ?
	AH	WO 08/095192	8/7/2008	PCT			
	AI	WO 08/157514	12/24/2008	PCT			

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
	AJ	Cook (1998) Antisense Medicinal Chemistry, Springer, New York, pp.51-101.
	AK	Dresser, MJ (2001) "The MDR1 C3425T polymorphism: effects on P-glycoprotein expression/function and clinical significance," AAPS PharmSci, 3(23):3, Clinical Pharmacology
	AL	Handbook of Pharmaceutical Excipients, (Arthur H. Kibbe, Ph.D., ed. American Pharmaceutical Association 2000) (1986)
	AM	Halin et al., (2002) "Enhancement of the antitumor activity of interleukin-12 by targeted delivery to neovasculature," Nature Biotech 20:264-269.
	AN	Heidel, Jeremy et al., (2005) "Molecular Conjugates," Adv. Biochem. Engin./Biotechnol: 99, 7-39.
	AO	Kong, Garheng et al., (2000) "Hyperthermia Enables Tumor-specific Nanoparticle Delivery: Effect of Particle Size," Cancer Research, 60:4440-4445.
	AP	Nagano et al., "Extracellular matrix modulates the proliferation of rat astrocytes in serum-free culture," Glia, 8:71-76
	AQ	Schneider, Holm et al., (1999) "Targeted gene delivery into $\alpha_5\beta_1$ -integrin-displaying cells by a synthetic peptide," FEBS Letters, 458:329-332.
	AR	Smith, James G. and Ho, Isaac, (1972) "The Reductive Dimerization of Schiff Bases by Alkali Metals. Isomerization of the Dimeric Dianions," Journal of Organic Chemistry, 37(4):653-656.
	AS	S.T. CROOKE, Chapter 1: Basic Principles on Antisense Therapeutics pp. 1-50.
	AT	Summerton and Weller (1997) Antisense Nuc. Acid Drug Devel. 7:187-195.
EXAMINER		DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

S:\Client\Folders\0269 (Gene Segues, Inc)\01\CIDS 12.doc

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE List of Information Cited by Applicant Page 2 of 2	ATTY. DOCKET NO. 0269.01/C	SERIAL NO. 10/652,814
	APPLICANT Unger	
	FILING DATE August 29, 2003	GROUP 1633

U.S. PATENT DOCUMENTS							
EXAM. INITIAL		DOCUMENT NUMBER	DATE	NAME	CLS	SUB- CLS	FILE DATE
	AU						
	AV						
	AW						
	AX						
	AY						
	AZ						
	AAA						
	ABB						
	ACC						

FOREIGN PATENT DOCUMENTS							
EXAM. INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLS	SUB CLS	TRANS ?
	BA						
	BB						
	BC						

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)		
BD	Wang (2006) "CK2 Signaling in androgen-dependent and independent prostate cancer" J. Cell Biochem. 99(2):382-391.	
BE	Wong (1991) "Chemistry of Protein Conjugation and Cross-Linking" CRC Press	
BF	Yamamoto et al., (1999) "Induction of Tenascin-C in Cardiac Myocytes by Mechanical Deformation," J. Biol. Chem. 274(31):21840-21846.	
BG	Yuan et al., (1994) "Microvascular Permeability and Interstitial Penetration of Sterically Stabilized (Stealth) Liposomes in a Human Tumor Xenograft" Cancer Research 54:3352-3356.	
BH	Zhang et al., (1997) "Comparison of Integrins in Human Skin, Pig Skin, and Perfused Skin: An In Vitro Skin Toxicology Model" Journal of Applied Toxicology 17(4):247-253	
EXAMINER	/Ileana Popa/	DATE CONSIDERED 05/27/2010
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.		

S:\Client\Folders\0269 (Gene Segues, Inc)\01\C\IDS 12.doc